S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
RAPP · Rapport Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Rapport Therapeutics Inc (RAPP)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$25.01
-4.31
(-14.70%)
● At close: October 21 at 4:00:00 PM EDT
$25.48
+0.42
(+1.68%)
Overnight:
9:37:52 PM EDT
DAY'S RANGE
$25.01
$24.85
$29.70
52-WEEK RANGE
$25.01
$23.75
$52.93
What's happening
- RAPP is down 14.70% today, trading at $25.01. — Live quote
- Volume today (77,672) is well below its 3-month average of 463,010. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.19 actual vs. $-0.97 estimated (-22.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (19 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
RAPP
-3.20%
vs S&P 500
-15.97%
1-YEAR RETURN
RAPP
+11.12%
vs S&P 500
-3.44%
6-MONTH RETURN
RAPP
-25.72%
3-MONTH RETURN
RAPP
-30.99%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.19
Est. $-0.97
MISS -22.3%
2026-04-26 (Q1 2026)
$-0.42
Est. $-0.68
BEAT +38.6%
2026-01-26 (Q4 2025)
$-0.72
Est. $-0.69
MISS -4.1%
2025-10-26 (Q3 2025)
$-0.71
Est. $-0.79
BEAT +10.2%
Valuation Measures & Ratios
Enterprise Value4$1.35B
Forward P/E5—
PEG Ratio6-0.41
Price / Sales (TTM1)—
Price / Book74.71
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-29.02%
Return on Assets (ROA9)-27.37%
Avg Volume (3M)463,010
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.99B | $1.49B | $1.13B | $406.7M | $354.9M |
| P/E | -15.26 | -15.24 | -11.86 | -4.70 | -4.31 |
| Price/Book | 4.70 | 3.15 | 2.21 | 1.54 | 1.24 |
| EV/EBITDA | -13.39 | -12.83 | -8.19 | — | — |
| ROE | -30.77% | -20.69% | -18.62% | -32.81% | -28.82% |
| ROA | -28.35% | -19.61% | -17.79% | -30.28% | -27.28% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,194,008
Change from Prior Settlement+42.08%
% of Float—
Days to Cover (Short Ratio)4.84
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +11.1%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-10-21; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on RAPP
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $20.0M | — | $0 | $0 | — | — | — |
| Operating income | -$60.8M | -$24.2M | -$30.0M | -$29.5M | -$27.1M | -$21.6M | -$20.8M | -$17.1M |
| Net income | -$56.6M | -$19.9M | -$26.9M | -$26.7M | -$24.1M | -$17.5M | -$18.1M | -$22.7M |
| EPS (diluted) | $-1.19 | $-0.42 | $-0.71 | $-0.75 | $-0.68 | $-0.50 | $-1.70 | $-11.07 |
| EPS (basic) | $-1.19 | $-0.42 | $-0.71 | $-0.75 | $-0.68 | $-0.50 | $-1.70 | $-11.07 |
| Operating margin | — | -$121 | — | — | — | — | — | — |
| Net margin | — | -$99 | — | — | — | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $459.0M | $497.6M | $512.4M | $535.3M | $285.5M | $302.1M | $314.9M | $331.1M |
| Total liabilities | $36.1M | $26.1M | $27.8M | $23.7M | $22.0M | $16.2M | $9.5M | $8.0M |
| Stockholders' equity | $422.9M | $471.5M | $484.7M | $511.6M | $263.5M | $285.8M | $305.4M | $323.1M |
| Total current assets | $446.9M | $484.7M | $498.6M | $520.7M | $270.2M | $291.0M | $309.8M | $325.9M |
| Total current liabilities | $28.4M | $17.9M | $19.0M | $14.3M | $11.9M | $9.4M | $8.8M | $7.1M |
| Cash & equivalents | $63.6M | $78.1M | $52.6M | $251.4M | $55.1M | $57.6M | $56.8M | $39.3M |
| Marketable securities (current) | $372.5M | $398.7M | $437.9M | $261.7M | $205.4M | $227.8M | $248.5M | $281.3M |
| Accounts receivable | $293.0K | $58.0K | $0 | — | — | — | — | — |
| Property, plant & equipment | $2.3M | $2.5M | $3.0M | $3.1M | $3.2M | $3.4M | $3.5M | $3.4M |
| Other non-current assets | $1.1M | $1.1M | $985.0K | $1.1M | $1.0M | $211.0K | $160.0K | $189.0K |
| Accounts payable | $2.8M | $6.6M | $4.2M | $3.2M | $3.2M | $2.1M | $2.0M | $1.3M |
| Accrued liabilities | $23.2M | $8.7M | $12.1M | $8.6M | $6.9M | $6.2M | $6.1M | $5.1M |
| Common stock & paid-in capital | $48.0K | $48.0K | $48.0K | $48.0K | $37.0K | $37.0K | $37.0K | $36.0K |
| Retained earnings | -$311.7M | -$255.1M | -$235.2M | -$201.5M | -$174.5M | -$147.8M | -$123.7M | -$103.8M |
| Accumulated other comprehensive income (loss) | -$1.3M | -$505.0K | $546.0K | $145.0K | -$76.0K | -$95.0K | -$522.0K | $400.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$41.5M | -$13.1M | -$24.7M | -$17.5M | -$25.1M | -$20.2M | -$14.4M | -$16.4M |
| Investing cash flow | $25.6M | $37.9M | -$174.3M | -$56.8M | $22.6M | $21.0M | $31.9M | -$53.0M |
| Financing cash flow | $1.4M | $531.0K | $311.0K | $270.5M | -$63.0K | $5.0K | $7.0K | -$1.4M |
| Free cash flow | -$41.5M | -$13.1M | -$24.9M | -$17.6M | -$25.1M | -$20.5M | -$14.7M | -$16.6M |
| Capital expenditures | $78.0K | $86.0K | $169.0K | $134.0K | $22.0K | $291.0K | $226.0K | $140.0K |
| Depreciation & amortization | $212.0K | $227.0K | $265.0K | $256.0K | $252.0K | $244.0K | $260.0K | $219.0K |
| Share-based compensation | $7.2M | $7.0M | $5.7M | $4.7M | $4.4M | $4.0M | $3.2M | $3.2M |
| Change in accounts receivable | $235.0K | $58.0K | — | — | $0 | $0 | — | — |
| Change in accounts payable | -$3.7M | $2.3M | $1.2M | -$179.0K | $1.0M | $185.0K | $648.0K | $46.0K |
| Purchases of investments | $39.7M | $30.4M | $197.1M | $101.6M | $12.9M | $43.2M | $84.6M | $109.7M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating income | -$125.1M | -$83.1M | -$36.2M |
| Net income | -$111.5M | -$78.3M | -$34.8M |
| EPS (diluted) | $-2.86 | $-3.78 | $-23.10 |
| EPS (basic) | $-2.86 | $-3.78 | $-23.10 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $512.4M | $314.9M | $155.4M | — |
| Total liabilities | $27.8M | $9.5M | $14.5M | — |
| Stockholders' equity | $484.7M | $305.4M | -$25.6M | -$10.1M |
| Total current assets | $498.6M | $309.8M | $150.9M | — |
| Total current liabilities | $19.0M | $8.8M | $8.8M | — |
| Cash & equivalents | $52.6M | $56.8M | $70.2M | — |
| Marketable securities (current) | $437.9M | $248.5M | $77.3M | — |
| Property, plant & equipment | $3.0M | $3.5M | $1.9M | — |
| Other non-current assets | $985.0K | $160.0K | $551.0K | — |
| Accounts payable | $4.2M | $2.0M | $2.5M | — |
| Accrued liabilities | $12.1M | $6.1M | $5.6M | — |
| Common stock & paid-in capital | $48.0K | $37.0K | $4.0K | — |
| Retained earnings | -$235.2M | -$123.7M | -$45.4M | — |
| Accumulated other comprehensive income (loss) | $546.0K | -$522.0K | $4.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$87.5M | -$64.8M | -$27.2M |
| Investing cash flow | -$187.5M | -$170.1M | -$78.9M |
| Financing cash flow | $270.8M | $221.6M | $145.1M |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M |
| Capital expenditures | $616.0K | $2.4M | $1.6M |
| Depreciation & amortization | $1.0M | $839.0K | $112.0K |
| Share-based compensation | $18.9M | $10.2M | $3.5M |
| Change in accounts payable | $2.2M | -$346.0K | $856.0K |
| Purchases of investments | $354.8M | $377.5M | $77.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding RAPP as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-04-17 to 2026-10-21
Recent transactions
- Insiders have net sold 597,769 shares over the last 182 days, across 1 purchase and 33 sales.
- Most recent: Ignelzi Troy A. (Chief Financial Officer) — Open market purchase of 5,500 shares on 2026-10-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)5,500 sh(1 txns)
Sales (open market)603,269 sh(33 txns)
Net Shares-597,769
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Ignelzi Troy A. | Chief Financial Officer | Open market purchase | 2026-10-21 | 5,500 |
| Ceesay Abraham | Chief Executive Officer | Open market sale | 2026-10-07 | 1,147 |
| Gault Cheryl | Chief Operating Officer | Open market sale | 2026-09-30 | 7,925 |
| Yeleswaram Krishnaswamy | Chief Development Officer | Open market sale | 2026-08-25 | 20,799 |
| Third Rock Ventures V, L.P. | Reporting person | Open market sale | 2026-05-26 | 18,572 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-21 | Ignelzi Troy A. | Chief Financial Officer | Open market purchase | 5,500 | $26.10 |
| 2026-10-07 | Ceesay Abraham | Chief Executive Officer | Open market sale | 1,147 | $30.66 |
| 2026-10-06 | Ceesay Abraham | Chief Executive Officer | Open market sale | 3,375 | $32.03 |
| 2026-09-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 7,925 | $33.04 |
| 2026-09-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 2,075 | $33.76 |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Open market sale | 1,952 | $39.05 |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Open market sale | 215 | $39.86 |
| 2026-09-23 | Ceesay Abraham | Chief Executive Officer | Open market sale | 43 | $41.05 |
| 2026-09-08 | Ceesay Abraham | Chief Executive Officer | Open market sale | 7,141 | $45.55 |
| 2026-09-08 | Ceesay Abraham | Chief Executive Officer | Open market sale | 1,069 | $46.01 |
| 2026-08-25 | Ceesay Abraham | Chief Executive Officer | Open market sale | 18,921 | $49.57 |
| 2026-08-25 | Yeleswaram Krishnaswamy | Chief Development Officer | Open market sale | 20,799 | $50.31 |
| 2026-08-25 | Yeleswaram Krishnaswamy | Chief Development Officer | Open market sale | 16,201 | $51.06 |
| 2026-08-24 | Yeleswaram Krishnaswamy | Chief Development Officer | Open market sale | 13,160 | $50.00 |
| 2026-08-19 | Yeleswaram Krishnaswamy | Chief Development Officer | Open market sale | 404 | $49.90 |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Open market sale | 3,664 | $46.90 |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Open market sale | 19,500 | $48.04 |
| 2026-08-11 | Ceesay Abraham | Chief Executive Officer | Open market sale | 5,794 | $48.62 |
| 2026-08-10 | Ceesay Abraham | Chief Executive Officer | Open market sale | 14,171 | $45.97 |
| 2026-08-10 | Ceesay Abraham | Chief Executive Officer | Open market sale | 8,370 | $46.75 |
| 2026-07-27 | Ceesay Abraham | Chief Executive Officer | Open market sale | 2,203 | $42.11 |
| 2026-07-27 | Ceesay Abraham | Chief Executive Officer | Open market sale | 7 | $42.73 |
| 2026-07-14 | Ceesay Abraham | Chief Executive Officer | Open market sale | 5,481 | $39.72 |
| 2026-07-14 | Ceesay Abraham | Chief Executive Officer | Open market sale | 2,729 | $40.57 |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 1,900 | $40.09 |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 3,792 | $41.39 |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 3,308 | $42.17 |
| 2026-06-30 | Gault Cheryl | Chief Operating Officer | Open market sale | 1,000 | $43.15 |
| 2026-06-29 | Ceesay Abraham | Chief Executive Officer | Open market sale | 7,344 | $39.77 |
| 2026-06-29 | Ceesay Abraham | Chief Executive Officer | Open market sale | 876 | $40.34 |
| 2026-05-26 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 18,572 | $40.05 |
| 2026-05-11 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 133,618 | $40.24 |
| 2026-05-08 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 5,018 | $40.31 |
| 2026-05-07 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 271,495 | $40.12 |
| 2026-04-17 | Third Rock Ventures V, L.P. | Reporting person | Open market sale | 426,005 | $40.32 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:08 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-21 | 4 | 2026-10-21 | View on SEC.gov → |
| 2026-10-20 | 8-K | 2026-10-20 | View on SEC.gov → |
| 2026-10-08 | 4 | 2026-10-06 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-09-24 | 4 | 2026-09-23 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-25 | View on SEC.gov → |
| 2026-08-26 | 4 | 2026-08-24 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-19 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-05 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-05 | 8-K | 2026-08-05 | View on SEC.gov → |
Recent news
Headlines about RAPP (Rapport Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Rapport Therapeutics CFO Troy Ignelzi buys $143,550 in company stock
Investing.com India · 2026-10-21 -
At $26.10 a share, Rapport Therapeutics (RAPP) CFO buys 5,500 shares.
Stock Titan · 2026-10-21 -
Jones Trading raises Rapport Therapeutics price target on RAP-219 trial wins
Investing.com Nigeria · 2026-10-21 -
Jones Trading raises Rapport Therapeutics price target on pipeline potential By Investing.com
Investing.com Nigeria · 2026-10-21 -
Wells Fargo cuts Rapport Therapeutics price target on FOS risk
Investing.com India · 2026-10-21 -
Wells Fargo Maintains Overweight on Rapport Therapeutics, Lowers Price Target to $50
Benzinga · 2026-10-21 -
Guggenheim Maintains Buy on Rapport Therapeutics, Raises Price Target to $70
Benzinga · 2026-10-21 -
Guggenheim raises Rapport Therapeutics price target to $70 on trial data
Investing.com Nigeria · 2026-10-21
No headlines in this category right now — try “All”.